Trial Profile
A Phase II, Randomized, Dose-scheduling, Observer-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of Vi-DT Conjugate Vaccine in 6-23-Month Old Healthy Filipino Infants and Toddlers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2021
Price :
$35
*
At a glance
- Drugs Typhoid vaccine Vi DT conjugate International Vaccine Institute/Incepta/SK Bioscience/PT Biofarma (Primary) ; Influenza virus vaccine
- Indications Typhoid
- Focus Adverse reactions; Therapeutic Use
- 26 Aug 2021 Status changed from active, no longer recruiting to completed.
- 01 Oct 2019 Primary endpoint (Immunogenicity endpoint) has been met, according to the results published in the Vaccine.
- 01 Oct 2019 Results of the interim analysis, published in the Vaccine